Crispr Therapeutics AG's total assets for Q3 2024 were $2.26B, a decrease of -3.58% from the previous quarter. CRSP total liabilities were $316.47M for the fiscal quarter, a -11.82% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.